The effect of etanercept on a case of amyloidosis secondary to ankylosing spondylitis: results of 2-year follow-up
Küçük Resim Yok
Tarih
2013
Yazarlar
Dergi Başlığı
Dergi ISSN
Cilt Başlığı
Yayıncı
Publisaude-Edicoes Medicas Lda
Erişim Hakkı
info:eu-repo/semantics/closedAccess
Özet
Secondary amyloidosis (type AA) is rarely encountered but can be a significant complication of ankylosing spondylitis (AS) and may lead to proteinuria and renal dysfunction. Anti-tumor necrosis factor-alpha (anti-TNF-alpha) agents may be used to induce clinical remission by suppressing systemic inflammation in secondary amyloidosis. The patient described, with the diagnosis of AS, was diagnosed with secondary amyloidosis, despite treatment with disease modifying anti-rheumatic medication. He developed marked proteinuria, renal dysfunction and low levels of serum albumin. Diagnosis of amyloidosis was confirmed by renal biopsy During a 2-year treatment period with etanercept, an anti-TNF-alpha agent, a definite improvement was determined in all parameters. This case illustrates that in the treatment of secondary amyloidosis related to AS, etanercept, an anti-TNF-alpha agent, can be considered an effective therapeutic option.
Açıklama
Anahtar Kelimeler
Ankylosing Spondylitis, Secondary Amyloidosis, Etanercept, Renal Function
Kaynak
Acta Reumatologica Portuguesa
WoS Q Değeri
Q4
Scopus Q Değeri
Q3
Cilt
38
Sayı
4
